

Stefania Paolucci

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1652018/stefania-paolucci-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

109 papers	3,517 citations	34 h-index	56 g-index
129 ext. papers	4,146 ext. citations	6 avg, IF	5.09 L-index

#	Paper	IF	Citations
109	SARS-CoV-2 infections in pediatric patients: A comparison of three pandemic waves.. <i>Pediatric Allergy and Immunology</i> , 2022 , 33 Suppl 27, 93-95	4.2	0
108	Spread of multiple SARS-CoV-2 lineages April-August 2020 anticipated the second pandemic wave in Lombardy (Italy).. <i>Pediatric Allergy and Immunology</i> , 2022 , 33 Suppl 27, 89-92	4.2	0
107	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.. <i>JHEP Reports</i> , 2022 , 4, 100462	10.3	1
106	SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. <i>Nature Communications</i> , 2021 , 12, 6032	17.4	16
105	EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. <i>International Journal of Infectious Diseases</i> , 2021 , 104, 315-319	10.5	22
104	A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1443-1451	3.4	0
103	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021 , 74, 801-810	13.4	12
102	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. <i>Liver International</i> , 2021 , 41, 1802-1814	7.9	8
101	No evidence of SARS-CoV-2 circulation in the framework of influenza surveillance between October 2019 and February 2020 in Lombardy, Italy. <i>Travel Medicine and Infectious Disease</i> , 2021 , 40, 102002	8.4	4
100	Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study. <i>International Journal of Infectious Diseases</i> , 2021 , 109, 199-202	10.5	10
99	Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report. <i>BMC Infectious Diseases</i> , 2021 , 21, 994	4	1
98	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo Covid19 Registry (SMACORE). <i>Microorganisms</i> , 2020 , 8,	4.9	157
97	Outbreak of hepatitis C virus infections originating from a breach in safe injection practices before contrast-enhanced computed tomography scanning. <i>Journal of Hospital Infection</i> , 2020 , 106, 600-604	6.9	1
96	Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. <i>Journal of Hospital Infection</i> , 2020 ,	6.9	39
95	Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre. <i>Journal of Hospital Infection</i> , 2020 ,	6.9	22
94	Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. <i>Journal of Medical Virology</i> , 2020 , 92, 1724-1727	19.7	152
93	SARS Cov-2 infection in a renal-transplanted patient: A case report. <i>American Journal of Transplantation</i> , 2020 , 20, 1882-1884	8.7	67

92	Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs. <i>Viruses</i> , 2020 , 12,	6.2	1
91	Myocardial localization of coronavirus in COVID-19 cardiogenic shock. <i>European Journal of Heart Failure</i> , 2020 , 22, 911-915	12.3	572
90	Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. <i>Eurosurveillance</i> , 2020 , 25,	19.8	86
89	Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1094.e1-1094.e5	9.5	86
88	Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing COVID19 epidemics in Lombardy. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1569-1571	9.5	2
87	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3349-3358	5.1	7
86	Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy. <i>Pediatric Allergy and Immunology</i> , 2020 , 31, 72-74	4.2	3
85	Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. <i>Journal of Hepatology</i> , 2019 , 71, 1106-1115	13.4	36
84	Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations. <i>Infection and Drug Resistance</i> , 2019 , 12, 1975-1984	4.2	3
83	No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference. <i>Antiviral Research</i> , 2019 , 172, 104635	10.8	5
82	Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort. <i>HIV Medicine</i> , 2019 , 20, 137-146	2.7	9
81	Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2019 , 70, 379-387	13.4	87
80	12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis. <i>Digestive and Liver Disease</i> , 2018 , 50, 703-706	3.3	
79	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018 , 68, 597-600	13.4	23
78	Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA). <i>Journal of Clinical Virology</i> , 2018 , 105, 112-117	14.5	9
77	Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. <i>Scientific Reports</i> , 2018 , 8, 8988	4.9	30
76	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy113	1	34
75	Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 777.e1-777.e4	9.5	5

74	HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy. <i>Antiviral Therapy</i> , 2017 , 22, 365-368	1.6	6
73	Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies. <i>Journal of Hepatology</i> , 2017 , 66, S82-S83	13.4	2
72	Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs. <i>Scientific Reports</i> , 2017 , 7, 16017	4.9	22
71	Occurrence of Extended Spectrum β -Lactamases, KPC-Type, and MCR-1.2-Producing from Wells, River Water, and Wastewater Treatment Plants in Oltrepò Pavese Area, Northern Italy. <i>Frontiers in Microbiology</i> , 2017 , 8, 2232	5.7	58
70	First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing. <i>Journal of Clinical Virology</i> , 2016 , 78, 1-3	14.5	3
69	Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement. <i>World Journal of Gastroenterology</i> , 2015 , 21, 1915-26	5.6	70
68	Development and persistence of DAA resistance associated mutations in patients failing HCV treatment. <i>Journal of Clinical Virology</i> , 2015 , 72, 114-8	14.5	14
67	Skewed B cells in chronic hepatitis C virus infection maintain their ability to respond to virus-induced activation. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 391-8	3.4	26
66	The novel influenza A virus protein PA-X and its naturally deleted variant show different enzymatic properties in comparison to the viral endonuclease PA. <i>Nucleic Acids Research</i> , 2015 , 43, 9405-17	20.1	38
65	Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. <i>Infection</i> , 2014 , 42, 61-71	5.8	7
64	Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 17-24	1.6	5
63	Systematic analysis of human oncogenic viruses in colon cancer revealed EBV latency in lymphoid infiltrates. <i>Infectious Agents and Cancer</i> , 2014 , 9, 18	3.5	22
62	Phylogenetic analysis of HIV type 1 CRF02_AG in multiple genes in Italian and African patients living in Italy. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 812-8	1.6	1
61	Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy. <i>HIV Clinical Trials</i> , 2014 , 15, 45-50		7
60	Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients. <i>Virology Journal</i> , 2013 , 10, 355	6.1	72
59	Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4pos T cells and macrophages. <i>Retrovirology</i> , 2013 , 10, 154	3.6	29
58	Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012 , 22, 2094-8	2.9	68
57	Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV. <i>Journal of Virological Methods</i> , 2012 , 184, 103-5	2.6	6

56	Next generation of antiretroviral agents targeting the RNA binding site of the HIV-1 cellular cofactor DDX3: an innovative therapeutic approach. <i>Retrovirology</i> , 2012 , 9,	3.6	78
55	Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy. <i>Clinical Microbiology and Infection</i> , 2012 , 18, E66-70	9.5	4
54	Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients. <i>Virology Journal</i> , 2012 , 9, 245	6.1	68
53	Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. <i>Journal of General Virology</i> , 2012 , 93, 889-899	4.9	46
52	HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America. <i>PLoS ONE</i> , 2012 , 7, e42223	3.7	16
51	Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. <i>New Microbiologica</i> , 2012 , 35, 17-25	1.1	19
50	The PDZ-ligand and Src-homology type 3 domains of epidemic avian influenza virus NS1 protein modulate human Src kinase activity during viral infection. <i>PLoS ONE</i> , 2011 , 6, e27789	3.7	12
49	Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009. <i>Clinical Microbiology and Infection</i> , 2011 , 17, 1352-5	9.5	6
48	HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients. <i>Virology Journal</i> , 2011 , 8, 149	6.1	15
47	Toward the discovery of novel anti-HIV drugs. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validation. <i>ChemMedChem</i> , 2011 , 6, 1371-89	3.7	73
46	Accumulation of defective HIV-1 variants in a patient with slow disease progression. <i>Current HIV Research</i> , 2011 , 9, 17-22	1.3	6
45	Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 425-33	5.1	48
44	Genetic divergence of influenza A NS1 gene in pandemic 2009 H1N1 isolates with respect to H1N1 and H3N2 isolates from previous seasonal epidemics. <i>Virology Journal</i> , 2010 , 7, 209	6.1	6
43	Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. <i>Journal of Medical Virology</i> , 2010 , 82, 116-22	19.7	39
42	Inhibitors of human immunodeficiency virus-1 replication targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase. <i>Retrovirology</i> , 2010 , 7,	3.6	78
41	HIV-1 plasma variants encoding truncated reverse transcriptase (RT) in a patient with high RT-specific CD8+ memory T-cell response. <i>Current HIV Research</i> , 2009 , 7, 302-10	1.3	4
40	Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell-depleted HLA-haploidentical stem cell transplantation. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 3672-7	9.7	43
39	HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. <i>Journal of Immunology</i> , 2008 , 180, 5907-15	5.3	41

38	Screening and Management of HIV-2-Infected Individuals in Northern Italy. <i>AIDS Patient Care and STDs</i> , 2008 , 22, 489-94	5.8	9
37	Changes in circulation of B and non-B HIV strains: spotlight on a reference centre for infectious diseases in Northern Italy. <i>Journal of Medical Virology</i> , 2008 , 80, 947-52	19.7	19
36	NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine. <i>Antiviral Research</i> , 2007 , 76, 99-103	10.8	8
35	Quantification and identification of polyomavirus DNA in blood and urine of renal transplant recipients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007 , 57, 301-7	2.9	6
34	Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility. <i>Antiviral Research</i> , 2006 , 69, 181-5	10.8	11
33	Detection and pathogenicity of human metapneumovirus respiratory infection in pediatric Italian patients during a winter--spring season. <i>Journal of Clinical Virology</i> , 2006 , 35, 59-68	14.5	49
32	Human cytomegalovirus UL131A, UL130 and UL128 genes are highly conserved among field isolates. <i>Archives of Virology</i> , 2006 , 151, 1225-33	2.6	39
31	Monoclonal antibodies versus reverse transcription-PCR for detection of respiratory viruses in a patient population with respiratory tract infections admitted to hospital. <i>Journal of Medical Virology</i> , 2005 , 75, 336-47	19.7	51
30	Changing circulation rate of human metapneumovirus strains and types among hospitalized pediatric patients during three consecutive winter-spring seasons. Brief report. <i>Archives of Virology</i> , 2005 , 150, 2365-75	2.6	51
29	Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 4611-7	5.9	18
28	Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations conferring drug resistance to HIV-1 variants. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 53, 766-71	5.1	5
27	Assays for determination of HIV resistance to antiviral drugs. <i>Current Drug Metabolism</i> , 2004 , 5, 317-9	3.5	4
26	Strategies to Decrease Viral Load Rebound, and Prevent Loss of Cd4 and Onset of Resistance during Structured Treatment Interruptions. <i>Antiviral Therapy</i> , 2004 , 9, 123-132	1.6	6
25	Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine. <i>Aids</i> , 2003 , 17, 1568-70	3.5	17
24	Processivity and drug-dependence of HIV-1 protease. <i>Aids</i> , 2003 , 17, 663-671	3.5	24
23	Nevirapine resistance mutation at codon 181 of the HIV-1 reverse transcriptase confers stavudine resistance by increasing nucleotide substrate discrimination and phosphorolytic activity. <i>Journal of Biological Chemistry</i> , 2003 , 278, 15469-72	5.4	16
22	Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naïve and HAART-experienced HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 51, 135-9	5.1	9
21	Detection of a new HIV-1 reverse transcriptase mutation (Q145M) conferring resistance to nucleoside and non-nucleoside inhibitors in a patient failing highly active antiretroviral therapy. <i>Aids</i> , 2003 , 17, 924-7	3.5	10

20	Emergence of multiple drug-resistant human cytomegalovirus variants in 2 patients with human immunodeficiency virus infection unresponsive to highly active antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2002 , 34, 1146-9	11.6	13
19	Analysis of HIV drug-resistant quasiespecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naïve and HAART patients. <i>Journal of Medical Virology</i> , 2001 , 65, 207-17	19.7	40
18	Higher levels of HIV DNA in memory and naïve CD4(+) T cell subsets of viremic compared to non-viremic patients after 18 and 24 months of HAART. <i>Antiviral Research</i> , 2001 , 50, 197-206	10.8	9
17	The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitors. <i>Journal of Biological Chemistry</i> , 2001 , 276, 44653-62	5.4	8
16	Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART. <i>Antiviral Research</i> , 2000 , 45, 101-14	10.8	22
15	Higher short-term virologic efficacy of three-class versus two-class highly active antiretroviral salvage therapy in HIV-infected patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2000 , 19, 380-4	5.3	3
14	Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the cognate epitope. <i>European Journal of Immunology</i> , 1999 , 29, 3629-35	6.1	36
13	Diagnostic and prognostic value of human cytomegalovirus load and IgM antibody in blood of congenitally infected newborns. <i>Journal of Clinical Virology</i> , 1999 , 14, 57-66	14.5	89
12	CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: lack of association with mutations other than CCR5-Delta32. <i>Journal of Virology</i> , 1998 , 72, 6215-7	6.6	48
11	Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection. <i>European Journal of Immunology</i> , 1997 , 27, 3166-73	6.1	37
10	Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 9848-53	11.5	174
9	Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon. <i>Journal of Viral Hepatitis</i> , 1995 , 2, 251-6	3.4	11
8	Adenoma-Carcinoma Sequence of Colorectum. <i>Diagnostic Molecular Pathology</i> , 1995 , 4, 198-202		11
7	Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. <i>Journal of Clinical Microbiology</i> , 1995 , 33, 16-23	9.7	29
6	Chronic liver disease and active hepatitis C virus infection in patients with antibodies to this virus. <i>Journal of Clinical Pathology</i> , 1994 , 47, 148-51	3.9	6
5	Presence of hepatitis C virus (HCV) genomic RNA and viral replicative intermediates in bone marrow and peripheral blood mononuclear cells from HCV-infected patients. <i>Vaccine Journal</i> , 1994 , 1, 160-3		29
4	Direct detection of HBV preC mutants in heterogeneous viral populations by a modified DNA sequencing method. <i>Research in Virology</i> , 1993 , 144, 303-6		4
3	Hepatitis B virus preC mutants in human hepatocellular carcinoma tissues. <i>Research in Virology</i> , 1993 , 144, 297-301		15

- 2 A human hepatoma cell line (PCL/PRF/5) produces lung metastases and secretes HBsAg in nude mice. *European Journal of Cancer & Clinical Oncology*, **1982**, 18, 381-9 10
- 1 SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers 1